astrazeneca

AstraZeneca password lapse exposed patient data

Pharmaceutical giant AstraZeneca has blamed “user error” for leaving a list of credentials online for more than a year that exposed access to sensitive patient data. Mossab Hussein, chief

As UK Gov reaches out to tech, investors threaten to ‘pull capital’ over M&A regulator over-reach

U.K. competition regulators are spooking tech investors in the country with an implied threat to clamp down on startup M&A, according to a new survey of the industry. As the U.K.’s Chancellor of

Facebook changes misinfo rules to allow posts claiming COVID-19 is man-made

Facebook made a few noteworthy changes to its misinformation policies this week, including the news that the company will now allow claims that COVID was created by humans — a theory that contradict

FDA authorizes Moderna’s COVID-19 vaccine for emergency use

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Moderna’s COVID-19 vaccine, as expected after an independent panel commissioned by the administrat

AWS expands on SageMaker capabilities with end-to-end features for machine learning

Nearly three years after it was first launched, Amazon Web Services’ SageMaker platform has gotten a significant upgrade in the form of new features, making it easier for developers to automate

Moderna claims 94% efficacy for COVID-19 vaccine, will ask FDA for emergency use authorization today

Drugmaker Moderna has completed its initial efficacy analysis of its COVID-19 vaccine from the drug’s Phase 3 clinical study, and determined that it was 94.1% effective in preventing people from

AstraZeneca says it will likely do another study of COVID-19 vaccine after accidental lower dose shows higher efficacy

AstraZeneca’s CEO told Bloomberg that the pharmaceutical company will likely conduct another global trial of the effectiveness of its COVID-19 vaccine trial, following the disclosure that the mo

Oxford University’s COVID-19 vaccine shows high efficacy, and is cheaper to make and easier to store

Oxford University’s COVID-19 vaccine, being developed in partnership with drugmaker AstraZeneca, has shown to be 70.4% effective in preliminary results from its Phase 3 clinical trial. That rate

The US now seems to be pinning all of its hopes on COVID-19 therapies and vaccines

Almost eight months after the White House first announced it would move from containment to mitigation efforts to stop the spread of the COVID-19 epidemic, the administration is now pinning its hopes

As it closes in on Arm, Nvidia announces UK supercomputer dedicated to medical research

As Nvidia continues to work through its deal to acquire Arm from SoftBank for $40 billion, the computing giant is making another big move to lay out its commitment to investing in U.K. technology. To

Moderna set to start final-stage trial of its coronavirus vaccine by July

Pharmaceutical company Moderna told Bloomberg on Thursday that it’s on pace to begin the final-stage clinical trial of its vaccine for the novel coronavirus that causes COVID-19 by July. Moderna

BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery

BenevolentAI is an AI company where AI actually means something. Founded in 2013, it focuses on “accelerating the journey from data to medicines.” To achieve that, it has raised a whopping

Facebook says that Workplace now has 2M paying users

With Slack gearing up to go public and now seeing daily active users of 10 million with 85,000 organizations using it to help employees communicate with each other, Facebook today released some update

Lack of transparency in healthcare startups risks another Theranos implosion

Are more Theranos-style scandals looming for investors in healthcare startups? A team of researchers associated with the Meta-Research Innovation Center at Stanford thinks so. They’ve published

AstraZeneca commits ‘hundreds of millions’ to sequencing genomes of 2M people over 10 years

Pharmaceutical giant AstraZeneca today unveiled a ten-year project to sequence the genomes of two million people — with top-tier medical and tech partnerships and a nine-figure price tag. The result